South Korean vaccine developer SK Bioscience Co Ltd is expected to raise 1.5 trillion won ($1.33 billion) in the country’s largest IPO since 2017, after pricing the listing at the top of an indicative range, it said on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in